Sleep Fragmentation and Alzheimer’s Disease
睡眠碎片化与阿尔茨海默病
基本信息
- 批准号:10611958
- 负责人:
- 金额:$ 72.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:Abeta clearanceAccelerationAddressAffectAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer&aposs disease patientAlzheimer&aposs disease riskAmyloid beta-ProteinAnti-Inflammatory AgentsAstrocytesAttenuatedBiologicalBrainChronicCognitionCognitive deficitsCorrelative StudyDecelerationDementiaDemographic FactorsDepositionDevelopmentDisease ProgressionExhibitsFamilyFrequenciesHumanImpaired cognitionImpairmentInflammationInflammatoryKnock-in MouseLifeLife StyleLightLinkMediatingMediatorMedical HistoryMicrogliaModelingMoodsMusNerve DegenerationNoisePathologyPersonal SatisfactionPharmaceutical PreparationsPhasePhase I Clinical TrialsProcessRestRiskRoleScheduleSleepSleep DeprivationSleep DisordersSleep FragmentationsSleep disturbancesSlow-Wave SleepSocietiesSynapsesSystemTemperatureTestingTimeWorkabeta accumulationage relatedbeta amyloid pathologycircadiancircadian pacemakerdesignimprovedimprovement on sleepmiddle agemild cognitive impairmentmouse modelneuroinflammationneuropathologyneurotoxicnoise exposurenovelnovel strategiesnovel therapeutic interventionpharmacologicpre-clinicalpreventresponsesleep qualitysleep quantity
项目摘要
Chronic sleep disruption, resulting from work schedules, noise exposure, family obligations, sleep disorders, or
lifestyle choices, is a pervasive feature of contemporary life. Sleep problems affect up to 40% of AD patients,
may precede cognitive impairments by more than a decade, and worsen as the disease progresses. As well as
affecting mood and well-being, sleep disruption may drive the development of AD neuropathology for instance,
by reducing clearance of amyloid-β (Aβ) and by promoting a neurotoxic proinflammatory state involving
astrocytes and microglia. Sleep disruption can include reduced total sleep (sleep restriction [SR]), loss of deep
sleep (also known as slow-wave sleep [SWS], marked by large amplitude, low frequency electrical activity),
and fragmentation of sleep (SF) into shorter bouts. Fragmentation of the daily sleep-wake rhythm is associated
with greater risk of incident AD and earlier cognitive decline in older humans. In spite of these correlative
studies, whether or how chronic SF impacts the progression of AD has not been experimentally investigated.
SF may be a better model of the sleep disruption associated with AD than the traditional approach of SR. Our
studies of AD mouse models show that spontaneously occurring SF is associated with more severe Aβ
accumulation and that experimentally-induced SF leads to Aβ accumulation and neuroinflammation. Besides
SF, loss of SWS may exacerbate AD, and improving SWS may be beneficial in mild cognitive impairment
(MCI) or even in AD. Since sleep disruption adversely affects the development of AD-related neuropathology, it
is surprising that sleep enhancement (SE) strategies to consolidate sleep and increase SWS have not been
adequately explored to slow or reverse these effects. Our overall working hypothesis is that a change in the
quality of sleep, especially sleep fragmentation and loss of SWS, is more important than the quantity of sleep.
Further, we hypothesize that the mechanism underlying these effects is primarily neuroinflammation, at least in
part mediated by Aβ peptide deposition. We will use a unique, well-characterized mouse model, that exhibits
AD-related Aβ pathology, neuroinflammation, and cognitive deficits. This project has three specific aims: (1)
that SF will accelerate (and SE decelerate) AD progression; (2) that increases in Aβ accumulation mediates
SF-induced neuroinflammation, neuropathology, and cognitive decline; and (3) that increases in
neuroinflammation mediate SF-induced neuropathology and cognitive decline. We will use multiple novel
approaches, including thermoneutral temperature manipulation, and a unique anti-inflammatory compound that
has recently entered early stage clinical trials. Thus, these studies will elucidate the underlying mechanisms by
which sleep disruption is linked to AD and will lay the groundwork for new therapeutic strategies.
由于工作安排、噪音暴露、家庭义务、睡眠障碍或
生活方式的选择是当代生活的一个普遍特征,睡眠问题影响着高达 40% 的 AD 患者。
可能先于认知障碍十多年,并且随着疾病的进展而恶化。
影响情绪和健康,睡眠中断可能会导致 AD 神经病理学的发展,例如,
通过减少淀粉样蛋白-β (Aβ) 的清除并促进神经毒性促炎状态,包括
星形胶质细胞和小胶质细胞的睡眠中断可能包括总睡眠时间减少(睡眠限制 [SR])、深度睡眠丧失。
睡眠(也称为慢波睡眠 [SWS],以大幅度、低频电活动为特征),
睡眠(SF)的碎片化与每日睡眠-觉醒节律的碎片化有关。
尽管存在这些相关性,但老年人患 AD 的风险更大,认知能力更早下降。
研究表明,慢性 SF 是否或如何影响 AD 的进展尚未得到实验研究。
与传统的 SR 方法相比,SF 可能是 AD 相关睡眠中断的更好模型。
AD 小鼠模型的研究表明,自发发生的 SF 与更严重的 Aβ 相关
此外,实验诱导的 SF 会导致 Aβ 积累和神经炎症。
SF、SWS 丧失可能会使 AD 恶化,而改善 SWS 可能有益于轻度认知障碍
(MCI) 甚至 AD 中,由于睡眠中断会对 AD 相关神经病理学的发展产生不利影响。
令人惊讶的是,巩固睡眠和增加 SWS 的睡眠增强 (SE) 策略尚未得到实施。
我们的总体工作假设是,要进行充分的探索来减缓或扭转这些影响。
睡眠质量,尤其是睡眠碎片化和SWS丧失,比睡眠数量更重要。
此外,我们发现这些影响的机制主要是神经炎症,至少在
我们将使用一个独特的、特征良好的小鼠模型,该模型表现出 Aβ 肽沉积介导的部分。
AD 相关的 Aβ 病理学、神经炎症和认知缺陷该项目有三个具体目标:(1)
SF 将加速(和 SE 减缓)AD 进展 (2) 增加 Aβ 积累介导;
SF 引起的神经炎症、神经病理学和认知能力下降;以及 (3)
神经炎症介导SF引起的神经病理学和认知能力下降我们将使用多本小说。
方法,包括热中性温度控制和独特的抗炎化合物
最近已进入早期临床试验,因此,这些研究将通过以下方式阐明其潜在机制。
睡眠障碍与 AD 相关,将为新的治疗策略奠定基础。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Space-occupying brain lesions, trauma-related tau astrogliopathy, and ARTAG: a report of two cases and a literature review.
- DOI:10.1186/s40478-021-01152-3
- 发表时间:2021-03-23
- 期刊:
- 影响因子:7.1
- 作者:Bachstetter AD;Garrett FG;Jicha GA;Nelson PT
- 通讯作者:Nelson PT
The localization of molecularly distinct microglia populations to Alzheimer's disease pathologies using QUIVER.
- DOI:10.1186/s40478-023-01541-w
- 发表时间:2023-03-18
- 期刊:
- 影响因子:7.1
- 作者:Shahidehpour, Ryan K.;Nelson, Abraham S.;Sanders, Lydia G.;Embry, Chloe R.;Nelson, Peter T.;Bachstetter, Adam D.
- 通讯作者:Bachstetter, Adam D.
The amyloid-β peptide: Guilty as charged?
淀粉样β肽:有罪吗?
- DOI:10.1016/j.bbadis.2023.166945
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Murphy,MPaul;Buzinova,ValeriaA;Johnson,CarrieE
- 通讯作者:Johnson,CarrieE
Chronic Fragmentation of the Daily Sleep-Wake Rhythm Increases Amyloid-beta Levels and Neuroinflammation in the 3xTg-AD Mouse Model of Alzheimer's Disease.
- DOI:10.1016/j.neuroscience.2021.11.042
- 发表时间:2022-01-15
- 期刊:
- 影响因子:3.3
- 作者:Duncan MJ;Guerriero LE;Kohler K;Beechem LE;Gillis BD;Salisbury F;Wessel C;Wang J;Sunderam S;Bachstetter AD;O'Hara BF;Murphy MP
- 通讯作者:Murphy MP
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ADAM D BACHSTETTER其他文献
ADAM D BACHSTETTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ADAM D BACHSTETTER', 18)}}的其他基金
Drug repurposing for Alzheimer’s disease-related inflammation caused by a TBI
药物再利用,治疗 TBI 引起的阿尔茨海默病相关炎症
- 批准号:
10590132 - 财政年份:2023
- 资助金额:
$ 72.93万 - 项目类别:
Neuronal IL-1R1 Signaling in Mild Closed Head Injury
轻度闭合性头部损伤中的神经元 IL-1R1 信号转导
- 批准号:
10518172 - 财政年份:2022
- 资助金额:
$ 72.93万 - 项目类别:
Neuronal IL-1R1 Signaling in Mild Closed Head Injury
轻度闭合性头部损伤中的神经元 IL-1R1 信号转导
- 批准号:
10656547 - 财政年份:2022
- 资助金额:
$ 72.93万 - 项目类别:
Translational Approaches to Mitigate Enhanced Alzheimer’s Disease Risk Following a Mild TBI
减轻轻度 TBI 后阿尔茨海默病风险增加的转化方法
- 批准号:
10090757 - 财政年份:2021
- 资助金额:
$ 72.93万 - 项目类别:
Administrative Supplement to Sleep Fragmentation and Alzheimer's Disease
睡眠碎片化和阿尔茨海默病的行政补充
- 批准号:
10555721 - 财政年份:2020
- 资助金额:
$ 72.93万 - 项目类别:
Cell-Specific Actions of IL-1 / IL-1R1 Signaling Following Traumatic Brain Injury
脑外伤后 IL-1/IL-1R1 信号传导的细胞特异性作用
- 批准号:
10307112 - 财政年份:2018
- 资助金额:
$ 72.93万 - 项目类别:
相似国自然基金
高功率激光驱动低β磁重联中磁岛对电子加速影响的研究
- 批准号:12305275
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
U型离散顺流火蔓延非稳态热输运机理与加速机制研究
- 批准号:52308532
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
NOTCH3/HLF信号轴驱动平滑肌细胞表型转化加速半月板退变的机制研究
- 批准号:82372435
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
TWIST1介导的ITGBL1+肿瘤相关成纤维细胞转化加速结肠癌动态演化进程机制及其预防干预研究
- 批准号:82373112
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
实施科学视角下食管癌加速康复外科证据转化障碍机制与多元靶向干预策略研究
- 批准号:82303925
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Molecular Markers of Cerebrovascular Pathologies in Alzheimer's Disease and Related Dementias
阿尔茨海默病和相关痴呆症脑血管病理学的分子标志物
- 批准号:
10806855 - 财政年份:2023
- 资助金额:
$ 72.93万 - 项目类别:
Glymphatic impairment as a crucial factor in particulate matter exposure related development of Alzheimer's disease pathology
类淋巴系统损伤是与颗粒物暴露相关的阿尔茨海默病病理学发展的关键因素
- 批准号:
10718104 - 财政年份:2023
- 资助金额:
$ 72.93万 - 项目类别:
Microglia dysregulation and SYK signaling in Alzheimer's disease
阿尔茨海默病中的小胶质细胞失调和 SYK 信号传导
- 批准号:
10659670 - 财政年份:2023
- 资助金额:
$ 72.93万 - 项目类别:
GLO1/Aβ-mediated mitochondrial and synaptic injury in Alzheimer's disease
GLO1/Aβ 介导的阿尔茨海默病线粒体和突触损伤
- 批准号:
10639086 - 财政年份:2023
- 资助金额:
$ 72.93万 - 项目类别:
Estrogen Declines with Menopause: Impacts on the Medial Temporal Lobe Network and Emotional Memory in Aging Females at Genetic Risk for Alzheimer’s Disease
雌激素随更年期下降:对有阿尔茨海默病遗传风险的老年女性内侧颞叶网络和情绪记忆的影响
- 批准号:
10607612 - 财政年份:2023
- 资助金额:
$ 72.93万 - 项目类别: